Compare ADPT & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | MANE |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2019 | 2026 |
| Metric | ADPT | MANE |
|---|---|---|
| Price | $27.73 | $119.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $33.86 | ★ $187.33 |
| AVG Volume (30 Days) | ★ 2.1M | 563.6K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $10.85 | N/A |
| Revenue Next Year | $21.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $35.43 |
| 52 Week High | $32.21 | $156.63 |
| Indicator | ADPT | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 41.83 |
| Support Level | $24.02 | $106.18 |
| Resistance Level | $29.92 | $132.58 |
| Average True Range (ATR) | 1.71 | 8.63 |
| MACD | -0.09 | -3.06 |
| Stochastic Oscillator | 31.91 | 1.60 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.